Sahlgrenska Universitetssjukhuset

Nil Medical has developed a medical vest to help seriously ill children and adolescents with intravenous drip stands to regain their mobility. The company developed the ergonomic medical vest to conceal fluids, pumps and tubing within the garments, allowing children to play and move without restrictions. Nil Medical is currently conducting a national quality-of-life study in collaboration with Swedish healthcare to introduce it to the international market. “I learned about the challenge faced by children who are willing and able to play but are restricted in their movement due to being attached to an IV stand. After visiting the pediatric cancer ward, I felt inspired to address this issue using a user-centered design methodology,” said Martin Hanberger, an industrial design student at Norrlands Universitetssjukhus. ”It feels incredible to finally have a finished product after so many years of development – especially when we see how much the children appreciate it. Making things easier for them has always been our driving force”. The company developed an early prototype and tested it without being connected to any treatment or IV bags. After, a group of specialists in design, product development and CE marking of medical devices collaborated with experienced staff in the pediatric oncology department to develop the Nil Medical Vestpack. Researchers on the project established requirements and conducted risk analyses to ensure the vest was safe and user-friendly. Interviews with patients, families and healthcare providers were also integral to the development process. “One of the young users said, ‘I want it to be nothing,'” Hanberger said. “The name Nil (English for ‘zero’) was thus born from the freedom of movement that our medical vest provides. Those who use it no longer have to be confined to drip stands; instead, they can move freely, safely, and securely.” Quality of life study Nil Medical is conducting a quality of life study in Sweden for the Vestpack in collaboration with Region Jönköping, Sahlgrenska University Hospital, and Norrlands Universitetssjukhus. The goal is to introduce a CE-marked infusion vest to the international market, giving children new possibilities and greater freedom of movement. The company is developing the system and testing it in collaboration with the Umeå Biotech Incubator. “Umeå Biotech Incubator has extensive business development expertise, a solid reputation and track record, and a broad network of contacts,” Hanberger said. “We are really looking forward to start collaborating with UBI.”

TUESDAY, Sept. 10, 2024 -- A European epilepsy drug could be an effective treatment for sleep apnea , a new study suggests. Patients who took sulthiame had few pauses in their breathing while asleep, as well as higher levels of blood oxygen, according to clinical trial results presented Tuesday at the European Respiratory Society annual meeting in Vienna. “This suggests that sulthiame could be an effective treatment for obstructive sleep apnea, especially for those who find they cannot use the existing mechanical treatments” like a CPAP machine , said researcher Jan Hedner from Sahlgrenska University Hospital and the University of Gothenburg in Sweden. Sulthiame has never been approved for use in the United States, but it is used in Europe to treat epilepsy. It appears to quell seizures by increasing blood levels of an established anticonvulsant called phenytoin. The drug also targets the respiratory system by inhibiting an enzyme called carbonic anhydrase, which stimulates upper airway muscles, researchers explained. For the study, researchers recruited nearly 300 people being treated for sleep apnea at hospitals in Spain, France, Belgium, Germany and the Czech Republic. None of the patients were using CPAP machines or mouthpieces to keep their airways open during sleep. Three-fourths of the participants were prescribed sulthiame at different dosage levels, and the remaining quarter took a placebo pill. Those taking the highest dose of sulthiame had 40% to 50% better breathing at night than those on placebo, based on different measures of sleep apnea, researchers said. Sulthaime patients also felt less sleepy during the daytime, researchers said. The drug produced mild to moderate side effects like pins and needles, headache, fatigue and nausea. “People taking sulthiame in the trial had a reduction in obstructive sleep apnea symptoms such as stopping breathing during the night and feeling sleepy during the day,” Hedner said in a meeting news release. “Their average levels of oxygen in the blood were also improved with the treatment.” However, Hedner said further clinical trials are needed to confirm these benefits before sulthaime can be widely adopted as a treatment for sleep apnea. Head of the ERS meeting, Sophia Schiza , noted this is one of the first studies to suggest that a drug could help with sleep apnea. Schiza was not involved in the research. “The results are promising,” Schiza, a professor of respiratory and sleep medicine at the University of Crete in Greece, said in a news release. “We need to continue testing sulthiame and other treatments to understand their long-term effects, including any side effects.” Because these findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

TUESDAY, Sept. 10, 2024 -- A European epilepsy drug could be an effective treatment for sleep apnea, a new study suggests. Patients who took sulthiame had few pauses in their breathing while asleep, as well as higher levels of blood oxygen, according to clinical trial results presented Tuesday at the European Respiratory Society annual meeting in Vienna. “This suggests that sulthiame could be an effective treatment for obstructive sleep apnea, especially for those who find they cannot use the existing mechanical treatments” like a CPAP machine , said researcher Jan Hedner from Sahlgrenska University Hospital and the University of Gothenburg in Sweden. Sulthiame has never been approved for use in the United States, but it is used in Europe to treat epilepsy. It appears to quell seizures by increasing blood levels of an established anticonvulsant called phenytoin. The drug also targets the respiratory system by inhibiting an enzyme called carbonic anhydrase, which stimulates upper airway muscles, researchers explained. For the study, researchers recruited nearly 300 people being treated for sleep apnea at hospitals in Spain, France, Belgium, Germany and the Czech Republic. None of the patients were using CPAP machines or mouthpieces to keep their airways open during sleep. Three-fourths of the participants were prescribed sulthiame at different dosage levels, and the remaining quarter took a placebo pill. Those taking the highest dose of sulthiame had 40% to 50% better breathing at night than those on placebo, based on different measures of sleep apnea, researchers said. Sulthaime patients also felt less sleepy during the daytime, researchers said. The drug produced mild to moderate side effects like pins and needles, headache, fatigue and nausea. “People taking sulthiame in the trial had a reduction in obstructive sleep apnea symptoms such as stopping breathing during the night and feeling sleepy during the day,” Hedner said in a meeting news release. “Their average levels of oxygen in the blood were also improved with the treatment.” However, Hedner said further clinical trials are needed to confirm these benefits before sulthaime can be widely adopted as a treatment for sleep apnea. Head of the ERS meeting, Sophia Schiza , noted this is one of the first studies to suggest that a drug could help with sleep apnea. Schiza was not involved in the research. “The results are promising,” Schiza, a professor of respiratory and sleep medicine at the University of Crete in Greece, said in a news release. “We need to continue testing sulthiame and other treatments to understand their long-term effects, including any side effects.” Because these findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.